According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely ...

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely to ...

Our independent appraisal committee has approved the use of gene editing therapy exagamglogene autotemcel (exa-cel) for use in the NHS in England, providing a potential cure for some people with ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Cell and gene therapy presents a potential solution to these challenges, offering the possibility to treat diseases at a cellular or genetic level. However, as promising as these therapies are ...

LONDON, Jan 31 (Reuters) - Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care ...

Successes are building including recent FDA approvals for gene therapy products that treat cancer, hemophilia, and sickle cell diseases. Yet many more applications await. One of the most actively ...